Vascular access-specific health-related quality of life impacts among hemodialysis patients: qualitative development of the hemodialysis access-related quality of life (HARQ) instrument

Robert J Nordyke, Gina Nicholson, Shawn M Gage, Ted Lithgow, Jonathan Himmelfarb, Matthew B Rivara, Ron D Hays, Karen Woo, John Devin Peipert, Robert J Nordyke, Gina Nicholson, Shawn M Gage, Ted Lithgow, Jonathan Himmelfarb, Matthew B Rivara, Ron D Hays, Karen Woo, John Devin Peipert

Abstract

Background: End stage kidney disease and hemodialysis dependence are associated with impairments in health-related quality of life (HRQOL), which may be related to vascular access (VA). Few HRQOL measures are VA-specific and none differentiate HRQOL impact by VA type. We developed a VA-targeted HRQOL measure to distinguish the impact of fistulas, grafts and catheters.

Methods: We created an initial item pool based on literature review and then conducted focus groups at 4 US sites with 37 adults and interviews with nine dialysis clinicians about VA's impact on HRQOL. We then drafted the Hemodialysis Access-Related Quality of Life (HARQ) measure and cognitively tested it with 17 hemodialysis patients. Focus group and cognitive interview participants were diverse in age, gender, years on dialysis, and VA.

Results: We identified six domains for the HARQ: symptoms, physical functioning, emotional impacts, social and role functioning, sleep, and care-related burdens. Cognitive interviews indicated that items were easily understood and supported content validity. Attributing HRQOL impact to VA as opposed to other hemodialysis burden was challenging for some items. Some items were dropped that were considered redundant by patients, limitations while dressing was added, and reference to VA-specific impact was included for each item. The average Flesch-Kincaid reading grade level for the revised 47-item HARQ was 5.3.

Conclusions: The HARQ features VA-specific content not addressed in other HRQOL measures, making it ideal for comparisons of different VA types and new VA technologies. The psychometric properties of the HARQ will be evaluated in future research.

Keywords: Hemodialysis; Qualitative development; Quality of life; Vascular access.

Conflict of interest statement

RJN and GN are employed by Beta6 Consulting Group which received funding from Humacyte for this study. SMG and TL are employees and stockholders of Humacyte, Incorporated. JH, MR, RDH, and JDP report no potential conflicts.

Figures

Fig. 1
Fig. 1
Study Flow
Fig. 2
Fig. 2
Conceptual framework for symptoms and HRQOL impacts
Fig. 3
Fig. 3
Article Yield from the Literature Review

References

    1. Quinn RR, Lamping DL, Lok CE, Meyer RA, Hiller JA, Lee J, Richardson EP, Kiss A, Oliver MJ. The vascular access questionnaire: assessing patient-reported views of vascular access. J Vasc Access. 2008;9:122–128. doi: 10.1177/112972980800900208.
    1. Taylor MJ, Hanson CS, Casey JR, Craig JC, Harris D, Tong A. "You know your own fistula, it becomes a part of you" - patient perspectives on vascular access: a semi-structured interview study. Hemodial Int. 2016;20:5–14. doi: 10.1111/hdi.12340.
    1. Casey JR, Hanson CS, Winkelmayer WC, Craig JC, Palmer S, Strippoli GF, Tong A. Patients' perspectives on hemodialysis vascular access: a systematic review of qualitative studies. Am J Kidney Dis. 2014;64(6):937–953. doi: 10.1053/j.ajkd.2014.06.024.
    1. Verberne WR, Das-Gupta Z, Allegretti AS, Bart HAJ, van Biesen W, García-García G, Gibbons E, Parra E, Hemmelder MH, Jager KJ, Ketteler M, Roberts C, Al Rohani M, Salt MJ, Stopper A, Terkivatan T, Tuttle KR, Yang CW, Wheeler DC, Bos WJW. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the international consortium for health outcomes measurement (ICHOM) CKD working group. Am J Kidney Dis. 2019;73(3):372–384. doi: 10.1053/j.ajkd.2018.10.007.
    1. Hurst FP, Lee RE, Thompson AM, Pullin BD, Silverstein DM. FDA regulatory perspectives for studies on hemodialysis vascular access. Clin J Am Soc Nephrol. 2018;13:513–518. doi: 10.2215/CJN.02900317.
    1. Shenoy S, Allon M, Beathard G, Brouwer-Maier D, Dember LM, Glickman M, Lee C, Litchfield T, Lok C, Huber T, Roy-Chaudhury P, Work J, West M, Wasse H. Clinical trial end points for hemodialysis vascular access: background, rationale, and definitions. Clin J Am Soc Nephrol. 2018;13(3):490–494. doi: 10.2215/CJN.13321216.
    1. Peipert JD, Hays RD. Expanding the Patient's voice in nephrology with patient-reported outcomes. J Am Soc Nephrol. 2019;30(4):654–663. doi: 10.1681/ASN.2018100994.
    1. Field M, Tullett K, Khawaja A, Jones R, Inston NG. Quality improvement in vascular access: the role of patient-reported outcome measures. J Vasc Access. 2019. 10.1177/1129729819845624.
    1. Viecelli AK, Tong A, O’Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM. Report of the standardized outcomes in nephrology-hemodialysis (SONG-HD) consensus workshop on establishing a Core outcome measure for hemodialysis vascular access; SONG-HD vascular access workshop investigators. Am J Kidney Dis. 2018;71(5):690–700. doi: 10.1053/j.ajkd.2017.12.003.
    1. Urquhart-Secord R, Craig JC, Hemmelgarn B, Tam-Tham H, Manns B, Howell M, Polkinghorne KR, Kerr PG, Harris DC, Thompson S, Schick-Makaroff K, Wheeler DC, van Biesen W, Winkelmayer WC, Johnson DW, Howard K, Evangelidis N, Tong A. Patient and caregiver priorities for outcomes in hemodialysis: an international nominal group technique study. Am J Kidney Dis. 2016;68:444–454. doi: 10.1053/j.ajkd.2016.02.037.
    1. Viecelli AK, O’Lone E, Sautenet B, Craig JC, Tong A, Chemla E, Hooi LS, Lee T, Lok C, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Irish AB, Mori TA, Pascoe EM, Johnson DW, Hawley CM. Vascular access outcomes reported in maintenance hemodialysis trials: a systematic review. Am J Kidney Dis. 2018;71(3):382–391. doi: 10.1053/j.ajkd.2017.09.018.
    1. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality-of-life (KDQOL) instrument. Qual Life Res. 1994;3(5):329–338. doi: 10.1007/BF00451725.
    1. Peipert JD, Nair D, Klicko K, Schatell DR, Hays RD. Kidney disease quality of life 36-item short form survey (KDQOL-36) normative values for the United States Dialysis population and new single summary score. J Am Soc Nephrol. 2019;30(4):654–663. doi: 10.1681/ASN.2018100994.
    1. Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, Yount S, Cook KF, Gershon RC, Amtmann D, DeWalt DA, Pilkonis PA, Stone AA, Weinfurt K, Reeve BB. PROMIS® adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019;22(5):537–544. doi: 10.1016/j.jval.2019.02.004.
    1. FDA. Guidance for industry on patient- reported outcome measures: Use in medical product development to support labeling claims. 2009. . Accessed 9 Jan 2020.
    1. Food and Drug Administration . Discussion Document for Patient-Focused Drug Development Public Workshop on Guidance 2: Methods to Identify What is Important to Patients. Silver Spring: United States Department of Health and Human Services; 2018.
    1. Wu AW, Fink NE, Cagney KA, Bass EB, Rubin HR, Meyer KB, Sadler JH, Powe NR. Developing a health-related quality-of-life measure for end-stage renal disease: the CHOICE health experience questionnaire. Am J Kidney Dis. 2001;37(1):11–21.
    1. Nunnally JC. Psychometric theory. 2. New York: McGraw-Hill; 1978.
    1. Fleiss J. Statistical methods for rates and proportions. Toronto: Wiley and Sons; 1981.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する